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Background: To our knowledge, no studies in patients with asthma have assessed a long-acting
muscarinic antagonist in the absence of inhaled corticosteroids (ICS).
Objective: Evaluate the doseeresponse, efficacy, and safety of umeclidinium (UMEC) in pa-
tients with asthma not receiving ICS.
Methods: In this double-blind, three-period crossover study, 350 subjects were randomized
to a sequence of three of eight inhaled treatments: UMEC 15.6, 31.25, 62.5, 125, or
250 mcg once daily (OD), UMEC 15.6 or 31.25 mcg twice daily (BID), or placebo, adminis-
tered for 14 days (12e14-day washout). Trough forced expiratory volume in one second
(FEV1), 0e24-h weighted mean (WM) FEV1, and safety were assessed. Serial spirometry
and pharmacokinetic assessments were performed in a subgroup.
Results: Subjects had a mean baseline pre- and post-bronchodilator FEV1 of 71% and 88%
predicted, respectively. Significant improvements in change from baseline trough FEV1
were observed for UMEC 15.6 OD (0.066 L; p Z 0.036) and UMEC 125 OD (0.088 L;
p Z 0.005) versus placebo, but not other OD or BID doses. UMEC increased 0e24-h WM
FEV1 versus placebo (0.068e0.121 L [p  0.017] with no clear doseeresponse). Treatmentcreted unchanged in urine; AE, adverse event; ALT, alanine aminotransferase; AUC, area under the
r minute; CI, confidence interval; Cmax, maximum plasma concentration; COPD, chronic obstructive
gram; Fe, percentage of total dose excreted in urine; FEV1, forced expiratory volume in one second;
gher limit of quantification; ICS, inhaled corticosteroid; ICH, International Conference on Harmo-
ratio; LAMA, long-acting muscarinic antagonist; LLQ, lower limit of quantification; LS, least squares;
; ND, not determined; NQ, non-quantifiable; OD, once daily; PEF, peak expiratory flow; PK, phar-
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64 L.A. Lee et al.differences were similar for corresponding OD and BID doses in serial assessments. UMEC
was rapidly absorbed, with evidence of some accumulation. The incidence of on-
treatment adverse events was 9e21% for UMEC and 12% for placebo. There were no
treatment-related effects on laboratory parameters.
Conclusion: The modest trough FEV1 improvements did not conclusively support a thera-
peutic benefit of UMEC in non-ICS treated patients with asthma.
ClinicalTrials.gov: NCT01641692.
ª 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Long-acting muscarinic antagonists (LAMAs) are well
established in guidelines for the treatment of chronic
obstructive pulmonary disease (COPD) [1]. Muscarinic an-
tagonists bind to M3 receptors, thereby blocking the action
of vagally-derived acetylcholine and inhibiting airway
smooth muscle contraction [2]. Given that parasympathetic
nervous system dysfunction is well established in asthma,
manifested as an increase in the magnitude of diurnal
variation in pulmonary function, and increased airway
hyper-responsiveness after viral infection or allergen
exposure [3e5], LAMAs may also have therapeutic benefits
in asthma. In support of this, recent studies have shown
that the LAMA, tiotropium, improves asthma symptoms
and/or lung function when used as add-on therapy to low-
or medium-dose inhaled corticosteroid (ICS) [6,7], and re-
duces the risk of a severe asthma exacerbation when added
to ICS and long-acting b-agonist therapy [8].
Umeclidinium (UMEC) is a quinuclidine derivative and
potent anticholinergic with slow functional reversibility at
the human M3 receptor [9]. UMEC is approved as mainte-
nance treatment for COPD in the US and EU. It is not indi-
cated for treatment of asthma. Studies have shown that
once-daily (OD) and twice-daily (BID) UMEC doses are well
tolerated in patients with COPD, and significantly improve
lung function, dyspnea, and health status in comparison
with placebo [10e14].
To support the development program for an ICS/LAMA
fixed-dose combination for the treatment of asthma, the
objective of this study was to evaluate the doseeresponse,
efficacy and safety of UMEC in adult patients with asthma.Materials and methods
Study design
This was a multicenter, randomized, double-blind, placebo-
controlled, three-period crossover incomplete block study
(GlaxoSmithKline study: ALA116402; ClinicalTrials.gov
identifier: NCT01641692 [May 2012eFebruary 2013]). Pa-
tients were enrolled at 42 centers in Bulgaria, Germany,
Mexico, Peru, Poland, and the United States.
During each 14-day treatment period there were three
visits, at Days 1 and 14 of dosing and 24 h after the last
dose. A follow-up visit was performed approximately 7 days
following Treatment Period 3.The study was approved by a local Ethics Committee/
Institutional Review Board in each country, and was con-
ducted in accordance with the International Conference on
Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use, Good Clinical Practice
(ICH-GCP) Guidelines, all applicable subject privacy re-
quirements and the ethical principles outlined in the
Declaration of Helsinki, 2008 [15,16]. Written, informed
consent was obtained from each subject before any study
procedures were performed.
Patients
Eligible patients: were 18 years of age; had a history of
asthma for 6 months prior to Visit 1 (as defined by the
National Institutes of Health [17]); were using a non-
corticosteroid controller and/or a short-acting b-agonist
(ICS use was prohibited for 4 weeks prior to study start);
had a forced expiratory volume in one second (FEV1) of
60e85% predicted normal (as determined by Nutrition
Health and Examination Survey III reference equations)
[18]; demonstrated 12% and 0.200 L reversibility to
albuterol at Visit 1; and were capable of withholding
albuterol for 4 h prior to any study visit.
Patients were excluded if they: were of childbearing
potential (unless practicing acceptable birth control
methods); had a history of life-threatening asthma within
the last 5 years; had experienced an asthma exacerbation
within the 4 weeks prior to Visit 1 that required oral or
injected corticosteroids for 3 days, or an in-patient hos-
pitalization or emergency department visit due to asthma
that required systemic corticosteroids; had a respiratory
infection within 4 weeks of Visit 1; had any concurrent
respiratory disease or disease preventing the use of anti-
cholinergics or where the use of an anticholinergic could be
deleterious; had used tobacco products in the 6 months
prior to Visit 1 or a smoking history 10 pack-years; had a
severe milk protein allergy or specific drug allergies; had
used any prohibited medications; or had a condition that
would affect their ability to participate in the study ac-
cording to protocol specifications.
Subjects who did not meet the inclusion criteria at the
end of the run-in period were not eligible for randomiza-
tion. Additional exclusion criteria at randomization
included: clinically significant abnormal laboratory tests
during Visit 1, which were still abnormal upon repeat
analysis; a severe asthma exacerbation requiring the use of
systemic corticosteroids for 3 days; in-patient
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asthma that required systemic corticosteroids between
Visits 1 and 3; or evidence of a significant abnormality in
the 12-lead electrocardiogram (ECG) performed at Visit 1 or
12-lead Holter monitoring over a 24-h period prior to
randomisation.Procedures
For subjects meeting eligibility criteria, non-corticosteroid
controller medications were ceased 48 h before the
screening visit. Subjects were permitted to use a short-
acting b-agonist as needed until the day of screening (Visit
1). Subjects entered a 9e14-day run-in period after
screening, during which reversibility testing to ipratropium
bromide was performed (Visit 2). Subjects received four
puffs of ipratropium bromide, with FEV1 assessments per-
formed pre-dose and within 40 min post-dose. Eligible
subjects were stratified in a 1:2:2 ratio according to age
(18e29, 30e49 and 50 years), and were randomized at
Visit 3 to a sequence of three of eight potential treatments:
UMEC 15.6, 31.25, 62.5, 125, or 250 mcg OD, UMEC 15.6 or
31.25 mcg BID, or placebo. The 14-day treatment periods
were separated by 12e14-day washout periods. Treatment
Period 3 was followed by a 5e9-day washout period before
a follow-up visit.
All treatments were self-administered via dry powder
inhaler in the morning and evening from distinct inhalers
labeled ‘AM’ and ‘PM’. In order to maintain blinding, sub-
jects who were randomized to receive an OD dose in the
morning also received a placebo in the evening. All subjects
had albuterol provided as rescue medication throughout
the study, including during washout periods.
Subjects were randomized using SAS-generated codes
imported into a validated computerized system (Randall
Version 2.5, GlaxoSmithKline). The Registration and Medi-
cation Ordering System was used to register and randomize
subjects.Outcomes and assessments
Efficacy endpoints
The primary efficacy endpoint was change from baseline in
trough FEV1 on Day 15 of each treatment period. Baseline
was the pre-dose FEV1 on Day 1; trough FEV1 was
obtained 24 h after morning dosing on Day 14. Changes in
morning and evening peak expiratory flow (PEF) and rescue
albuterol use were assessed as secondary endpoints.
Change from baseline in morning pre-dose FEV1 (Day 14)
was assessed as an additional efficacy endpoint.
Weighted mean (WM) FEV1 24 h after morning dosing on
Day 14 and serial FEV1 at each time point over 24 h after
morning dosing on Day 14 were additional secondary end-
points examined in a serial assessment subgroup (consisting
of approximately 30% of the total population). Additional
spirometry parameters in the serial assessment subgroup
included WM FEV1 0e6 h after morning dosing (Days 1 and
14), WM FEV1 0e12 h after morning and evening dosing (Day
14), and serial FEV1 over 6 h after morning dosing (Days 1
and Day 14).Spirometry measurements (excluding those in the serial
assessment subgroup) were performed in the morning at all
clinic visits (Day 1, Day 14, and Day 15 of each treatment
period, and at follow-up). In the serial assessment sub-
group, measurements were performed pre-dose on Day 1
(within 1 h prior to dosing) and at 5, 15, and 30 min, and 1,
3, and 6 h post-dose. On Day 14 (continuing into Day 15),
FEV1 was measured pre-dose (within 1 h prior to dosing)
and at 5, 15, and 30 min, and 1, 3, 6, 9, 12, 16, 20, 23,
and 24 h post-dose. PEF, asthma symptoms, and rescue
albuterol use were recorded using electronic diaries
throughout the study, including screening and washout
periods, to identify any periods of asthma worsening.
Exploratory analyses
Exploratory analyses examined possible predictors of
change from baseline in trough FEV1, including age, sex,
body mass index, asthma duration, screening FEV1 and
FEV1/forced vital capacity (FVC) ratio, albuterol revers-
ibility, ipratropium reversibility, heart rate, systolic and
diastolic blood pressure, and the asthma control test [19].
Pharmacokinetic (PK) analyses
PK analyses on UMEC were performed on blood and urine
samples taken from the serial assessment subgroup. Blood
samples were collected pre-dose on Day 1 of each treat-
ment period (within 1 h prior to dosing) and at 5 and 15 min,
and 2 h post-dose. On Day 14, samples were collected pre-
dose and at 5 and 15 min, and 2 and 12 h after each of the
morning and evening doses. Urine samples were collected
on Day 1 of each treatment period at 0e6 h post-dose and
on Day 14 of each treatment period at 0e6 h, 6e9 h,
9e12 h, 12e14 h, and 14e24 h following the morning dose.
Plasma and urine samples were analyzed using validated
analytical method based on solid phase extraction, followed
by high-performance liquid chromatography with tandem
mass spectrometry. The lower limit of quantification for
UMEC in plasma and urine was 10.0 pg/mL, while the higher
limit of quantification was 2000 pg/mL in plasma and
5000 pg/mL in urine (York Bioanalytical Solutions, York, UK).
Safety
Safety assessments in all subjects included adverse events
(AEs), liver function, vital signs (including pulse and sys-
tolic/diastolic pressure), clinical chemistry, hematology
and urinalysis parameters, 12-lead ECG parameters, and
severe asthma exacerbations. In addition, serial ECG as-
sessments and 24-h Holter monitoring were performed in
the serial assessment subgroup.Sample sizes and statistical analyses
The study design provided 95% power to detect a 0.150 L
difference in FEV1 between any two treatments. It was
assumed that a Z 0.05, that the within-patient standard
deviation of FEV1 was 0.290 L, and that testing was two-
sided. A total of 350 subjects were randomized to ensure
that 270 completed all three double-blind treatment
periods.
Analyses were conducted in the intent-to-treat (ITT)
population (subjects randomized to treatment and
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(subjects in the ITT population for whom a PK sample was
obtained and analyzed). Doseeresponse analyses (using
linear and non-linear mixed-effects modeling) were con-
ducted for the primary endpoint. Other efficacy endpoints
were analyzed using mixed-model methods. Descriptive
statistics summarized safety data. WM FEV1 was defined as
the area under the FEV1 versus time curve (calculated using
the trapezoidal rule) divided by the relevant time interval.
PK parameters were derived by standard non-
compartmental analyses via Phoenix WinNONLIN Version
6.3 (Pharsight Corporation, California, USA). All other an-
alyses were performed via SAS Version 9 or NONMEM
Version 7.1.Results
Subjects
Of the 529 patients screened, 350 were randomized to
treatment and included in the ITT population, across 42Screened (N = 529)
Entered run-in (N = 410)
Randomized (N = 350)
Completed all treatment periods (N = 298)
ITT (N = 350)
UMEC OD
62.5 mcg
N = 133
31.25 mcg
N = 138
15.6 mcg
N = 131
15.6 mcg
N = 126
250 mcg
N = 135
125 mcg
N = 128N = 126
Placebo UME
Completed treatment period
UMEC OD
62.5 mcg
N = 124
31.25 mcg
N = 127
15.6 mcg
N = 123
15.6 mcg
N = 114
250 mcg
N = 119
125 mcg
N = 116N = 113
Placebo UME
Withdrawn during treatment period
UMEC OD
62.5 mcg
N = 0
31.25 mcg
N = 2
15.6 mcg
N = 1
15.6 mcg
N = 2
250 mcg
N = 4
125 mcg
N = 4N = 5
Placebo UME
Withdrawn during wash-out or follow-up
UMEC OD
62.5 mcg
N = 3
31.25 mcg
N = 5
15.6 mcg
N = 1
15.6 mcg
N = 4
250 mcg
N = 3
125 mcg
N = 7N = 5
Placebo UME
Figure 1 Subject disposition. BID, twice daily; ITT, incenters (United States, n Z 95 [27%]; Peru, n Z 87 [25%];
Bulgaria, n Z 61 [17%]; Poland, n Z 42 [12%]; Germany,
n Z 36 [10%], and Mexico, n Z 29 [8%]) (Fig. 1). In total,
298 subjects completed the study and 52 subjects were
withdrawn. The most common reason for withdrawal over
the course of the study (including treatment periods,
washout and follow-up) was reaching protocol-defined
stopping criteria (n Z 22 [6%]), including ECG abnormal-
ities (n Z 15 [4%]) and Holter abnormalities (n Z 8 [2%];
one subject was recorded with both an ECG abnormality
and a Holter abnormality) (further details in Supplementary
Tables 1 and 2).
The serial spirometry, PK, and ECG assessments, and
24-h Holter monitoring were performed in subjects ran-
domized at a subset of centers (128 subjects: United States,
n Z 37; Germany, n Z 28, Bulgaria, n Z 24; Poland,
n Z 21; and Peru, n Z 18).
The majority of subjects in the ITT population were
White, female, and had a diagnosis of asthma for 10 years
(Table 1). Most subjects (71%) had an asthma control test
score <20 at screening. Subjects had mild impairment in
airflow (mean pre-albuterol FEV1, 71%) and were reversible119 subjects not eligible
   • Did not meet inclusion/exclusion criteria (n = 117)
   • Investigator discretion (n = 1)
   • Withdrew consent (n = 1)
60 subjects were run-in failures
   • Did not meet continuation criteria (n = 46)
   • Withdrew consent (n = 6)
   • Investigator discretion (n = 4)
   • Study closed/terminated (n = 3)
   • Protocol deviation (n = 1)
30 subjects withdrew during wash-out period or follow-up
   • Protocol-defined stopping criteria reached (n = 18)
   • Withdrew consent (n = 8)
   • Adverse event (n = 2)
   • Protocol deviation (n = 2)
22 subjects withdrew during treatment
   • Withdrew consent (n = 6)
   • Protocol-defined stopping criteria reached (n = 4)
   • Protocol deviation (n = 4)  
   • Lost to follow-up (n = 3)
   • Adverse event (n = 2)
   • Lack of efficacy (n = 2)
   • Investigator discretion (n = 1)
31.25 mcg
N = 133
C BID
31.25 mcg
N = 121
C BID
31.25 mcg
N = 4
C BID
31.25 mcg
N = 2
C BID
tent-to-treat; OD, once daily; UMEC, umeclidinium.
Table 1 Baseline subject demographics and
characteristics.
Demographic characteristic Total (N Z 350)
Sex, n (%)
Female 232 (66)
Male 118 (34)
Age, years
Mean (SD) 42.6 (14.84)
Age group, n (%)
18e29 83 (24)
30e49 149 (43)
50 118 (34)
Race, n (%)
White 197 (56)
American Indian or Alaska Native 85 (24)
Black or African-American 33 (9)
Multiple 31 (9)
Asian 4 (1)
Ethnicity, n (%)
Hispanic/Latino 123 (35)
Not Hispanic/Latino 227 (65)
Body size, mean (SD)
BMI (kg/m2) 28.5 (6.42)
Asthma duration
6 months to <1 year 3 (<1)
1e<2 years 7 (2)
2e<5 years 26 (7)
5e<10 years 70 (20)
10e<15 years 54 (15)
15e<20 years 52 (15)
20e<25 years 54 (15)
25 years 84 (24)
Asthma control test score
Mean (SD) 16.6 (4.24)
Pre-albuterol FEV1 (L)
Mean (SD) 2.268 (0.5539)
Predicted pre-albuterol FEV1 (%)
Mean (SD) 71.33 (6.766)
Post-albuterol FEV1 (L)
Mean (SD) 2.794 (0.6880)
Predicted post-albuterol FEV1 (%)
Mean (SD) 87.91 (9.538)
Pre-ipratropium FEV1 (L)
Mean (SD) 2.330 (0.6139)
Post-ipratropium FEV1 (L) (n Z 349)
Mean (SD) 2.622 (0.6902)
FEV1 reversibility to albuterol (%)
Mean (SD) 23.46 (10.211)
FEV1 reversibility to ipratropium (%) (n Z 349)
Mean (SD) 13.21 (13.220)
BMI, body mass index; FEV1, forced expiratory volume in one
second; L, liters; SD, standard deviation.
Figure 2 Adjusted mean differences from placebo (95% CI) in
change from baseline in trough FEV1 (L) on Day 15. CI, confi-
dence interval; BID, twice daily; FEV1, forced expiratory vol-
ume in one second; OD, once daily; UMEC, umeclidinium.
Umeclidinium monotherapy in patients with asthma 67to albuterol (mean reversibility, 23.46% [n Z 350]) and
ipratropium (mean reversibility 13.21% [n Z 349]). Further
details on the asthma history of subjects are provided in
Supplementary Table 3. In the 30 days prior to Screening
Visit 1, asthma medications were used by 91% of subjects.The medications used most frequently in this period
were albuterol (71% of subjects), montelukast/montelukast
sodium (18%), and theophylline (5%).Efficacy outcomes
Trough FEV1 increased for all UMEC doses versus placebo in
the range of 0.011e0.088 L, but the least squares (LS) mean
change from baseline was statistically significantly
different from placebo only for UMEC 15.6 OD and UMEC 125
OD at Day 15 (Fig. 2; Table 2). Overall, treatment differ-
ences were similar for corresponding OD and BID doses, and
there was no clear doseeresponse in the change from
baseline in trough FEV1.
There were no statistically significant differences for
any UMEC dose versus placebo for morning PEF. UMEC 15.6
OD, 125 OD, 250 OD, and 31.25 BID produced statistically
significant improvements in evening PEF versus placebo,
with no clear doseeresponse (Supplementary Table 4).
Small reductions in rescue albuterol use were observed
(0.2e0.5 puffs/day), but the reductions were not signifi-
cantly different for UMEC versus placebo. Improvements in
the change from baseline in morning pre-dose FEV1 (Day 14)
were not statistically significant compared with placebo
(difference versus placebo: 0.005e0.050 L).
Serial spirometry assessments
In the subgroup of subjects with serial spirometry assess-
ments, all UMEC doses produced statistically significant in-
creases in 0e24-h WM FEV1 versus placebo (0.068e0.121 L)
(Table 3). The largest increases in FEV1 were observed at
3 h post-dose, and these improvements were statistically
significant compared with placebo (p  0.005), but there
was no apparent dose-ordering (Fig. 3). Responses to
UMEC administered BID were similar to those following the
corresponding OD doses. All UMEC doses produced statisti-
cally significant increases in 0e6 h WM FEV1 versus placebo
on Day 1 (except OD UMEC 31.25 and both BID doses) and on
Day 14 (Supplementary Table 5). Similar results were seen
for WM FEV1 0e12 h after morning and evening dosing
on Day 14 (Supplementary Table 6). There was no clear
doseeresponse in any of the serial spirometry assessments.
Table 2 Statistical analysis of change from baseline in trough FEV1 (L) at Day 15.
Trough FEV1 (L) Placebo UMEC OD
15.6 mcg 31.25 mcg 62.5 mcg 125 mcg 250 mcg
n 110 120 124 122 113 117
LS mean (SE) 2.398 (0.0235) 2.464 (0.0226) 2.428 (0.0222) 2.432 (0.0224) 2.486 (0.0232) 2.409 (0.0228)
LS mean change (SE) 0.046 (0.0235) 0.112 (0.0226) 0.076 (0.0222) 0.080 (0.0224) 0.134 (0.0232) 0.057 (0.0228)
Treatment vs Placebo
Difference 0.066 0.030 0.034 0.088 0.011
95% CI 0.004, 0.127 0.030, 0.090 0.027, 0.095 0.026, 0.149 0.050, 0.073
p-value 0.036 0.331 0.272 0.005 0.722
Trough FEV1 (L) UMEC BID
15.6 mcg 31.25 mcg
n 113 118
LS mean (SE) 2.455 (0.0232) 2.449 (0.0227)
LS mean change (SE) 0.103 (0.0232) 0.097 (0.0227)
Treatment vs Placebo
Difference 0.057 0.051
95% CI 0.006, 0.119 0.010, 0.113
p-value 0.076 0.101
Analysis performed using a mixed model, including treatment, period, period baseline FEV1 and mean baseline FEV1 as fixed effects and
subject as a random effect.
BID, twice daily; CI, confidence interval; FEV1, forced expiratory volume in one second; L, liters; LS, least squares; OD, once daily;
SE, standard error; UMEC, umeclidinium.
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Multiple statistically significant predictors of trough FEV1
response were identified in linear regression models
(Supplementary Table 7a). However, the Pearson correla-
tion coefficients for overall data and by treatment were lowTable 3 0e24-h WM FEV1 at Day 14.
WM FEV1 (L) Placebo UMEC OD
15.6 mcg 31.25
n 33 35 49
LS mean (SE) 2.309 (0.0255) 2.394 (0.0249) 2.410
LS mean change (SE) 0.025 (0.0255) 0.060 (0.0249) 0.077
Treatment vs placebo
Difference 0.085 0.101
95% CI 0.025, 0.145 0.047
p-value 0.006 <0.0
WM FEV1 (L) UMEC
15.6 m
n 35
LS mean (SE) 2.430
LS mean change (SE) 0.097
Treatment vs placebo
Difference 0.121
95% CI 0.061,
p-value <0.00
Note: Analysis performed using a mixed model, including treatment
effects and subject as a random effect.
BID, twice daily; CI, confidence interval; FEV1, forced expiratory vo
SE, standard error; UMEC, umeclidinium; WM, weighted mean.(range: 0.245 to 0.365) and the data did not indicate any
clinically-relevant predictors of response. When the sig-
nificant predictors from the linear regression models were
included in multiple regression models (overall and by
treatment), few significant predictors were identified and
the model multiple correlation coefficients were lowmcg 62.5 mcg 125 mcg 250 mcg
42 45 38
(0.0222) 2.426 (0.0232) 2.427 (0.0229) 2.382 (0.0243)
(0.0222) 0.092 (0.0232) 0.094 (0.0229) 0.048 (0.0243)
0.117 0.119 0.073
, 0.156 0.061, 0.173 0.064, 0.174 0.015, 0.131
01 <0.001 <0.001 0.014
BID
cg 31.25 mcg
43
(0.0252) 2.377 (0.0231)
(0.0252) 0.043 (0.0231)
0.068
0.182 0.012, 0.124
1 0.017
, period, period baseline FEV1 and mean baseline FEV1 as fixed
lume in one second; L, liters; LS, least squares; OD, once daily;
Figure 3 Adjusted mean change from baseline (95% CI) in
0e24-h serial FEV1 on Day 14. BID, twice daily; CI, confidence
interval; FEV1, forced expiratory volume in one second; LS,
least squares; OD, once daily; UMEC, umeclidinium.
Umeclidinium monotherapy in patients with asthma 69(overall, R2 Z 0.161 [Supplementary Table 7b]; by treat-
ment, all R2 < 0.227). Based on these findings, no pre-
dictors of trough FEV1 response were carried forward for
further inferential analysis.Pharmacokinetics
UMEC plasma concentrations peaked at approximately
5 min post-dose on Days 1 and 14. The median of the
last time point with quantifiable concentration (tlast) was
0.242e2.00 h for UMEC 15.6e250 OD on Day 1, and
0.250e24.00 h on Day 14. The median tlast was similar for
UMEC 15.6e31.25 BID on Day 1 and 14, at
0.233e0.250 h and 0.233e0.275 h, respectively (Table 4).
The mean maximum plasma concentration (Cmax) was
higher on Day 14 than Day 1 for all OD and BID UMEC doses
(Cmax was non-calculable for UMEC 15.6 OD) (Table 4).
The approximate dose proportionality of UMEC was
assessed based on Cmax, area under the curve
0e2 h (AUC0e2) in plasma and amount of UMEC excreted
unchanged (Ae) in the urine with power models. For Cmax
with OD dosing, the adjusted mean slopes (90% confidence
intervals [CI]) were 1.03 (0.90e1.16) on Day 1, and 1.20
(1.06e1.34) on Day 14 (only 62.5, 125, and 250 mcg doses
were analyzed due to the high proportion of non-calculable
values on other doses). It was not possible to calculate the
adjusted mean slope for AUC0e2 on Day 1 due to the high
proportion of non-quantifiable concentrations. At Day 14,
for AUC0e2, the adjusted mean slope was 1.11 (1.01e1.21).
Ae values on Day 14 indicated dose-proportionality for OD
doses of 15.6e250 mcg: Ae0e6 1.06 (0.92e1.20); Ae0e24 1.07
(1.00e1.14).
On Day 1 and Day 14, percentage of total UMEC dose
excreted in urine 0e6 h was approximately 0.5e1.4% of the
dose administered for all treatments. Over 24 h, the me-
dian amount of UMEC excreted was approximately 3% of the
dose after repeated administration of UMEC (Table 4).
Safety
The incidence of on-treatment AEs across all treatment
periods was 9e21% for UMEC, and 12% for placebo. The
most frequently reported on-treatment AE was headache(UMEC, 2e5%; placebo, 2%) and ‘product taste abnormal’
was more common at higher UMEC doses (Table 5).
Four subjects experienced on-treatment asthma exac-
erbations during the study (UMEC 15.6 BID, n Z 1;
UMEC 31.25 BID, n Z 1; placebo, n Z 2). Two non-fatal
serious AEs (SAEs) were reported, one spontaneous abor-
tion identified at the end of Treatment Period 3 (UMEC 250
OD) and one asthma exacerbation post-treatment (UMEC
62.5 OD). None of the non-fatal SAEs was considered
related to study treatment by the investigator and there
were no deaths during the study. Four subjects had non-
serious on-treatment AEs that led to study withdrawal
(UMEC 125 OD, nZ 1 [supraventricular tachycardia, an ECG
stopping criterion]; placebo, n Z 3 [ECG T-wave inversion,
throat irritation, and myalgia/eyelid edema).
There was no indication of treatment- or dose-related
changes in clinical chemistry, hematology, urinalysis
parameters or liver function tests over the course of the
study. However, for diastolic blood pressure it was noted
that the mean change from baseline in diastolic blood
pressure was greater in the placebo group (2.1 mmHg)
than the UMEC treatment groups (range: 0.8 to
0.6 mmHg). The difference was statistically significant be-
tween placebo and all UMEC OD treatment groups (except
UMEC 31.25 OD) and UMEC 15.6 BID (1.7e2.7 mmHg,
p  0.030).
Post-treatment ECG abnormalities occurred at a similar
rate across the treatment groups (UMEC, 38e48 subjects
[30e38%]; placebo, 38 subjects [30%]). The most common
abnormal finding was depolarization/repolarization
(frequent ventricular premature depolarization [3]),
which occurred in 20e32 subjects [15e25%] following UMEC
treatment and 21 subjects [17%] following placebo. A
similar incidence of Holter abnormalities were reported at
Day 14 in the placebo group (6 subjects [15%]) and UMEC
treatment groups (7e8 subjects [14e19%]), with the
exception of UMEC 15.6 OD where the incidence was lower
(3 subjects [7%]). Overall, there was no indication of
treatment-related effects in relation to ECG and Holter
findings.Discussion
The utility of LAMAs is well established in the treatment of
COPD, and tiotropium data in patients with asthma un-
controlled on an ICS-containing therapy are emerging
[1,6,8]. In the present study, the change in trough FEV1 at
Day 15 was <0.090 L for all UMEC doses compared with
placebo, with no consistency in the magnitude of the effect
or apparent doseeordered response. All UMEC doses were
associated with significant improvements in 0e24-h WM
FEV1 (0.068e0.121 L) compared with placebo yet also
without a doseeordered response. There was no indication
that BID dosing offered additional benefit over OD dosing.
These results are in line with studies of tiotropium in
asthma, which have failed to demonstrate a convincing
doseeresponse with the doses established for use in COPD
[20,21]. However, the data are in contrast to studies in
COPD where UMEC demonstrated a doseeordered response
in trough FEV1 across a similar range of OD doses [14]. It is
possible that the contrasting results may be explained by
Table 4 Summary of key UMEC pharmacokinetic parameters (plasma and urine) following morning dosing on Days 1 and 14.
UMEC treatment N Day 1 Day 14
n n* Median (Range) n n* Median (Range)
Plasma parameters
tmax (h) 15.6 OD 44 16 25 0.083 (0.05e0.25) 23 18 0.083 (0e12.05)
31.25 OD 55 37 15 0.083 (0e0.30) 45 6 0.083 (0e0.28)
62.5 OD 48 44 2 0.083 (0e0.25) 46 0 0.083 (0e12.25)
125 OD 53 49 0 0.083 (0.05e0.28) 45 1 0.083 (0e0.27)
250 OD 48 43 2 0.083 (0.05e0.33) 42 0 0.083 (0e0.25)
15.6 BID 42 20 20 0.083 (0e0.27) 30 9 0.083 (0e2.00)
31.25 BID 52 41 9 0.083 (0.05e0.25) 44 5 0.083 (0e2.00)
tlast (h) 15.6 OD 44 16 25 0.242 (0.05e0.25) 23 18 0.250 (0.05e12.05)
31.25 OD 55 37 15 0.250 (0.05e2.08) 45 6 0.250 (0.07e12.13)
62.5 OD 48 44 2 0.250 (0.08e2.08) 46 0 2.00 (0.18e24.17)
125 OD 53 49 0 2.00 (0.05e2.17) 45 1 23.967 (0.23e24.27)
250 OD 48 43 2 2.00 (0.27e2.15) 42 0 24.00 (2.07e24.5)
15.6 BID 42 20 20 0.233 (0.05e2.03) 30 9 0.233 (0.07e11.75)
31.25 BID 52 41 9 0.250 (0.05e0.25) 44 5 0.275 (0.05e11.95)
Geometric mean (95% CI) Geometric mean (95% CI)
Cmax (pg/mL) 15.6 OD 44 41 25 NA 41 18 10.52 (NC, 13.33)
31.25 OD 55 52 15 14.53 (11.57, 18.25) 51 6 24.04 (19.27, 29.98)
62.5 OD 48 46 2 48.42 (39.08, 59.98) 46 0 66.21 (55.75, 78.63)
125 OD 53 49 0 115.41 (96.03, 138.71) 46 1 131.65 (105.39, 164.44)
250 OD 48 45 2 183.78 (136.91, 246.7) 42 0 339.65 (282.16, 408.85)
15.6 BID 42 40 20 NA (NC, 10.93) 39 9 12.43 (10.29, 15.01)
31.25 BID 52 50 9 17.35 (13.93, 21.62) 49 5 28.91 (22.35, 37.39)
AUC0e2 (pg h/mL) 15.6 OD 44 33 33 NA 27 27 NA
31.25 OD 55 29 28 NA 17 12 NA
62.5 OD 48 11 3 38.02 (20.79, 69.52) 36 2 55.46 (46.27, 66.46)
125 OD 53 41 2 94.1 (77.34, 114.49) 44 1 124.29 (105.36, 146.64)
250 OD 48 44 2 169.71 (135.32, 212.85) 42 0 290.6 (257.15, 328.4)
15.6 BID 42 31 29 NA 26 23 NA
31.25 BID 52 20 20 NA 29 9 27.75 (21.03, 36.62)
Urine parameters
Geometric mean (95% CI) Geometric mean (95% CI)
Ae0e6 (mcg) 15.6 OD 44 39 2 0.092 (0.07, 0.120) 39 2 0.134 (0.106, 0.171)
31.25 OD 55 52 0 0.122 (0.07, 0.208) 51 0 0.288 (0.244, 0.340)
62.5 OD 48 46 0 0.032 (0.25, 0.40) 46 0 0. 532 (0.412, 0.688)
125 OD 53 49 0 0.868 (0.07, 1.07) 46 0 0.999 (0.506, 1.974)
250 OD 48 44 0 1.936 (1.60, 2.34) 42 0 3.278 (2.790, 3.850)
15.6 BID 42 40 0 0.094 (0.07, 0.12) 39 0 0.181 (0.145, 0.228)
31.25 BID 52 50 0 0.160 (0.13, 0.20) 48 1 0.286 (0.158, 0.519)
Ae0e24 (mcg) 15.6 OD 44 NA NA NA 38 1 0.376 (0.270, 0.523)
31.25 OD 55 NA NA NA 51 0 0.797 (0.688, 0.924)
62.5 OD 48 NA NA NA 45 0 1.815 (1.563, 2.107)
125 OD 53 NA NA NA 43 0 3.567 (2.781, 4.574)
250 OD 48 NA NA NA 40 0 7.812 (6.759, 9.029)
15.6 BID 42 NA NA NA 39 0 0.484 (0.394, 0.595)
31.25 BID 52 NA NA NA 48 0 1.014 (0.834, 1.232)
Median (Range) Median (Range)
Fe0e6 (%) 15.6 OD 44 39 2 0.516 (0.03e3.46) 39 2 1.014 (0.10e3.43)
31.25 OD 55 52 0 0.473 (0.00e4.14) 51 0 0.911 (0.17e2.81)
62.5 OD 48 46 0 0.631 (0.06e1.99) 46 0 1.001 (0.03e2.32)
125 OD 53 49 0 0.750 (0.08e2.74) 46 0 1.263 (0.00e5.29)
250 OD 48 44 0 0.769 (0.14e2.64) 42 0 1.266 (0.49e4.08)
15.6 BID 42 40 0 0.638 (0.10e3.69) 39 0 1.269 (0.20e5.30)
31.25 BID 52 50 0 0.517 (0.12e2.36) 48 1 1.378 (0.00e3.90)
Fe0e24 (%) 15.6 OD 44 NA NA NA 38 1 2.885 (0.03e9.39)
31.25 OD 55 NA NA NA 51 0 2.614 (0.50e8.39)
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Table 4 (continued )
UMEC treatment N Day 1 Day 14
n n* Median (Range) n n* Median (Range)
62.5 OD 48 NA NA NA 45 0 3.352 (0.71e6.99)
125 OD 53 NA NA NA 43 0 3.243 (0.14e9.24)
250 OD 48 NA NA NA 40 0 3.044 (1.30e7.87)
15.6 BID 42 NA NA NA 39 0 1.510 (0.39e5.36)
31.25 BID 52 NA NA NA 48 0 1.681 (0.32e7.62)
Geometric mean and CIs were not calculated if there were over 50% and 30% NC values, respectively. AUC was imputed with half the
lowest observed AUC, Cmax was imputed with half the LLQ (LLQ, 10 pg/mL).
Ae, amount of UMEC excreted unchanged in urine; AUC, area under the curve; BID, twice daily; CI, confidence interval; Cmax, maximum
plasma concentration; Fe, percentage of total UMEC dose excreted in urine; LLQ, lower limit of quantification; n, number of non-missing
values (including imputed NC values); n*, number of NC values; NA, not available; NC, non-calculable (due to presence of NQ values); ND,
not determined; NQ, non-quantifiable concentration measured as below LLQ; OD, once daily; tlast, time of the last point with quanti-
fiable concentration; tmax, time to maximum plasma concentration; UMEC, umeclidinium.
Umeclidinium monotherapy in patients with asthma 71differences in the levels of functional agonism in different
health and disease states.
The present study demonstrated a bronchodilator effect
of UMEC in subjects with asthma not requiring ICS treatment,
which was of a similar nature to that seen in healthy volun-
teers (data on file). To our knowledge, no other trials have
evaluated LAMAs for the treatment of asthma in the absence
of ICS therapy. The modest improvement in pulmonary
function could be a reflection of an asthma study population
in whom parasympathetic nervous system dysfunction does
not predominate. Supportive evidence for the benefit of
anticholinergic medications in asthma exists in selected
asthma populations, including those with nocturnal symp-
toms, or fixed airway obstruction, and in murine models of
chronic asthma, rather than across the broad spectrum ofTable 5 On-treatment AEs reported by 3% of subjects in any
Preferred term Number of subjects, n (%)
Placebo
N Z 126
UMEC OD
15.6 mcg
N Z 131
31.25 m
N Z 13
Any AE 15 (12) 12 (9) 13 (9)
Headache 2 (2) 5 (4) 4 (3)
Nasopharyngitis 1 (<1) 3 (2) 0
Product taste
abnormal
0 0 2 (1)
Pharyngitis 1 (<1) 0 1 (<1)
Preferred term UMEC BI
15.6 mc
Any AE 16 (13)
Headache 2 (2)
Nasopharyngitis 4 (3)
Product taste abnormal 1 (<1)
Pharyngitis 1 (<1)
On-treatment AEs were defined as AEs with onset within the period be
day after the last day of study drug administration.
AE, adverse event; BID, twice daily; OD, once daily; UMEC, umeclidinasthma severity [22e24]. Furthermore, a study of UMEC
combinedwith an OD ICS (fluticasone furoate) demonstrated
convincing evidence of a bronchodilating effect of UMEC in
patients with asthma uncontrolled on ICS, and further
showed that the effect was greater in patients with fixed
versus non-fixed obstruction [25].
Overall, the PK of UMEC in terms of both plasma con-
centration and urine extraction were consistent with pre-
vious studies of UMEC in healthy volunteers and patients
with COPD [11,14,26,27]. On Day 14, the high proportion of
non-quantifiable values for UMEC Cmax and AUC0e2 pre-
vented an accurate interpretation of dose proportionality.
However, in contrast to the plasma PK parameters, the
urinary recovery of unchanged UMEC over 24 h following
repeat dosing did show evidence of dose proportionality fortreatment group.
cg
8
62.5 mcg
N Z 133
125 mcg
N Z 128
250 mcg
N Z 135
21 (16) 26 (20) 28 (21)
5 (4) 4 (3) 6 (4)
1 (<1) 3 (2) 1 (<1)
1 (<1) 4 (3) 5 (4)
5 (4) 0 1 (<1)
D
g N Z 126 31.25 mcg N Z 133
12 (9)
6 (5)
2 (2)
0
0
ginning with the first day of study drug administration through the
ium.
72 L.A. Lee et al.OD doses. There was some evidence of accumulation with
repeat dosing, further studies would be needed to deter-
mine whether this had reached a plateau by Day 14 as
observed in the previous studies [11,26].
No safety concerns were identified from the clinical
chemistry and hematology data. Cardiovascular safety was
closely monitored in the study, particularly in the serial
subgroup where serial ECGs and 24-h Holter recording were
performed. Holter abnormalities (that did not meet exclu-
sion criteria) were identified in 20 of the subjects (16%)
with available Holter counts during screening (most
commonly recorded as ectopic supraventricular beats,
other abnormality/cardiologist comments and ventricular
premature depolarization), indicating a background inci-
dence of findings in the population studied. Most subjects
included in the study population had normal ECG or Holter
assessments at screening, although a high proportion of
abnormal ECGs not requiring exclusion were observed over
the study. Overall, the ECG and Holter data did not
raise safety concerns, as judged by the study
investigators, consistent with studies of UMEC in patients
with COPD [11].
Conclusions
In conclusion, the modest improvements in trough FEV1
following UMEC treatment were not dose-related or
consistent in magnitude, and therefore did not conclusively
support a therapeutic benefit of UMEC monotherapy in
patients with asthma not requiring ICS treatment. The re-
sults of this study, the first to evaluate LAMA monotherapy
in asthma, should be balanced with the preponderance of
data for LAMAs in the management of COPD [1] and
emerging evidence for their benefit in patients with
persistent asthma [6,8,25]. As LAMAs may not provide
effective bronchodilation in patients with asthma who do
not exhibit features of high cholinergic tone, adequate
characterization of the doseeresponse of UMEC in
asthma requires careful consideration of the subjects’
phenotype.
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